Rezolute completes enrollment in Phase 3 upLIFT study, results due mid‑December 2026
Rezolute Inc. announced that its open‑label Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism has finished enrolling 16 participants. The study’s primary endpoint is a ≥50% reduction in glucose infusion rate for participants requiring intravenous glucose. Seven of the first eight participants met the responder criterion, and the drug has been well‑tolerated so far. Topline data are slated for release in mid‑December 2026, and the company will keep its expanded access program active.
Why it matters
The upcoming topline data will determine whether the trial meets its statistical threshold and could drive regulatory decisions, affecting Rezolute’s valuation and investor sentiment. The company’s continuation of the expanded access program signals ongoing commitment to the therapy while awaiting trial results.
Key facts
- 1Enrollment was completed with 16 participants in the upLIFT study. investing.com
- 2Topline results are expected in mid‑December 2026. tradingview.com
- 3Seven of the first eight participants met the primary responder criterion. tradingview.com
- 4The primary endpoint measures a ≥50% reduction in glucose infusion rate for participants requiring intravenous glucose. investing.com
- 5Rezolute plans to continue its expanded access program for ersodetug on a compassionate‑use basis. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.